Compounds > gsk221149a
Page last updated: 2024-11-12

gsk221149a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GSK221149A: highly selective oxytocin receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11340891
CHEMBL ID429736
CHEBI ID188651
SCHEMBL ID230301
MeSH IDM0512721

Synonyms (37)

Synonym
820957-38-8
D08986
retosiban (usan)
gsk-221149a
gsk221149a
CHEMBL429736 ,
gsk-221149
gsk221149
CHEBI:188651
retosiban
(3r,6r)-6-[(2s)-butan-2-yl]-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
bdbm50372608
retosiban [usan:inn]
unii-gie06h28ox
gie06h28ox ,
gsk 221149a
morpholine, 4-((2r)-((3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-6-((1s)-1- methylpropyl)-2,5-dioxo-1-piperazinyl)(2-methyl-4-oxazolyl)acetyl)-
(3r,6r)-6-((2s)-butan-2-yl)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2-methyl- 1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl)piperazine-2,5-dione
retosiban [usan]
morpholine, 4-((2r)-2-((3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-6-((1s)-1-methylpropyl)-2,5-dioxo-1-piperazinyl)-2-(2-methyl-4-oxazolyl)acetyl)-
retosiban [inn]
(3r,6r)-6-[(2s)-butan-2-yl]-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione
(3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2.5-piperazinedione
PLVGDGRBPMVYPB-FDUHJNRSSA-N
(3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
SCHEMBL230301
DTXSID00231559
gsk-221,149-a
gtpl8403
2,5-piperazinedione, 3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-, (3r,6r)-
DB11818
HY-14778
CS-0003555
Q7316883
gsk 221149; gsk 221149a
MS-29186
AKOS040742542

Research Excerpts

Effects

ExcerptReferenceRelevance
"GSK221149A has been shown to inhibit oxytocin-induced uterine contractions in the anaesthetised rat."( The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Allen, MJ; Borthwick, AD; Brooks, DP; Davies, DE; Edwards, RM; Exall, AM; Hamlett, C; Hickey, DM; Irving, WR; Liddle, J; Mason, AM; McCafferty, GP; Nerozzi, F; Peace, S; Philp, J; Pollard, D; Pullen, MA; Shabbir, SS; Sollis, SL; Westfall, TD; Woollard, PM; Wu, C, 2008)		1.41

Toxicity

ExcerptReferenceRelevance
" Serious adverse events (SAEs) were primarily captured via CHI."( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study.
Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)		0.91
"The current study showed no unexpected adverse outcome or impairment with retosiban based on safety monitoring and neurodevelopment assessments."( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study.
Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)		0.91
"ยท There is a need for an effective and safe treatment for sPTL."( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study.
Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)		0.91

Bioavailability

ExcerptReferenceRelevance
" Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats."( Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
Allen, MJ; Borthwick, AD; Davies, DE; Exall, AM; Hamlett, C; Hickey, DM; Liddle, J; Mason, AM; Nerozzi, F; Peace, S; Pollard, D; Pullen, MA; Smith, IE; Sollis, SL; Stanislaus, DJ; Westfall, TD; Woollard, PM, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
" The study provides the rationale and dosing strategy for further evaluation of the efficacy of retosiban in the treatment of PTL."( Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study.
Baidoo, C; Clayton, L; Fossler, MJ; Montague, TH; Powell, M; Snidow, J; Soergel, D; Stier, B; Thornton, S; Valenzuela, G, 2017)		0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)100.00000.00011.753610.0000AID317406
Vasopressin V2 receptorHomo sapiens (human)Ki0.95000.00040.43453.9811AID317415
Oxytocin receptorHomo sapiens (human)Ki0.00190.00010.07180.9780AID317402; AID317412
Vasopressin V1a receptorHomo sapiens (human)Ki12.00000.00020.62357.0300AID317413
Vasopressin V1b receptorHomo sapiens (human)Ki10.00000.00050.18971.7820AID317414
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1b receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1b receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1b receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityVasopressin V1b receptorHomo sapiens (human)
regulation of cell population proliferationVasopressin V1b receptorHomo sapiens (human)
positive regulation of MAPK cascadeVasopressin V1b receptorHomo sapiens (human)
symbiont entry into host cellVasopressin V1b receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processVasopressin V1b receptorHomo sapiens (human)
positive regulation of arachidonic acid secretionVasopressin V1b receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1b receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1b receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1b receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1b receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1b receptorHomo sapiens (human)
peptide bindingVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endosomeVasopressin V1b receptorHomo sapiens (human)
Golgi apparatusVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID317419Decrease in oxytocin-induced uterine contractions in iv dosed non-pregnant Sprague-Dawley rat2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317411Bioavailability in rat at 2 mg/kg, iv or 5 mg/kg, po2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317414Binding affinity to human vasopressin V1b receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317413Binding affinity to human vasopressin V1a receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317410AUC in rat at 5 mg/kg, po in DMSO/PEG400 formulation2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317416Selectivity for human oxytocin receptor over human vasopressin V1a receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664081Intrinsic clearance in cynomolgus monkey liver microsomes2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317412Binding affinity to recombinant oxytocin receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513693Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V2 receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513682Displacement of [3H]-oxytocin from oxytocin receptor in human uterus tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID317409Half life in rat at 2 mg/kg, iv or 5 mg/kg, po2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513690Oral bioavailability in rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID317415Binding affinity to human vasopressin V2 receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664082Intrinsic clearance in human liver microsomes2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317402Binding affinity to human oxytocin receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317406Inhibition of CYP3A42008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317405Aqueous solubility of the compound2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664108Clearance in cynomolgus monkey at 2 mg/kg2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID664107AUC in cynomolgus monkey at 2 mg/kg, po2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317420AUC in rat at 5 mg/kg, po in HPMC/Tween formulation2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317404Binding affinity to human serum albumin2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317408Clearance in rat at 2 mg/kg, iv or 5 mg/kg, po2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317418Selectivity for human oxytocin receptor over human vasopressin V2 receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664109Oral bioavailability in cynomolgus monkey at 2 mg/kg2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317417Selectivity for human oxytocin receptor over human vasopressin V1b receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317407Selectivity for human oxytocin receptor over vasopressin V1a receptor2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513692Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V1a receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2007American journal of physiology. Regulatory, integrative and comparative physiology, Jul, Volume: 293, Issue:1
Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's8 (61.54)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (30.77%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (61.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.1110sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		2.1110inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
opc 21268
OPC 21268: structure given in first source; vasopressin V1 receptor antagonist		2.0510
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		4.4111aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		2.7530heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
atosiban
[no description available]		2.0410oligopeptide
l 372662
L 372662: structure in first source		2.0510
l 371257
L 371257: structure given in first source		2.0510
l 368899
[no description available]		2.0510
epelsiban
epelsiban: structure in first source		2.5320dipeptide
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		2.0310
obe001
OBE001: an oxytocin receptor antagonist		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		02.0310
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		07.7772
Preterm Birth
[description not available]		07.5352
Premature Birth
CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).		19.5352
Labor, Premature
[description not available]		06.2132